Product image of Mibezet (Ezetimibe) supplied by GNH India

Mibezet

Active Ingredient:
Ezetimibe
Origin:
EU

Mibezet (Ezetimibe)

Ezetimibe, the active ingredient in Mibezet, is a cholesterol absorption inhibitor presented as an oral tablet for oral use. It lowers blood cholesterol levels and is indicated for patients with hypercholesterolemia, heterozygous familial hypercholesterolemia, and primary hyperlipidemia. It is marketed across the European Union and conforms to EU pharmaceutical standards for patients requiring lipid management.

GNH India supplies Mibezet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global distribution.

Manufacturer / TM Owner

Win Medica Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ezetimibe, marketed as Mibezet, is used to lower cholesterol by reducing intestinal absorption, and is indicated for several lipid disorders.

  • Hypercholesterolemia: reduces LDL‑cholesterol levels, helping achieve target lipid goals in patients with elevated total cholesterol.
  • Heterozygous familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when combined with statin therapy in genetically predisposed individuals.
  • Primary hyperlipidemia: lowers total cholesterol and LDL‑cholesterol as part of a comprehensive lipid‑lowering regimen.

How It Works

  • Ezetimibe selectively blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter located on the brush border of enterocytes. By inhibiting this transporter, the drug prevents the uptake of dietary and biliary cholesterol from the intestinal lumen, leading to reduced delivery of cholesterol to the liver and up‑regulation of hepatic LDL receptors, which lowers circulating LDL‑cholesterol.

Side Effects

Ezetimibe is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects

  • Abdominal discomfort
  • Diarrhea
  • Fatigue
  • Headache
  • Joint pain
  • Nausea

Serious or Rare Side Effects

  • Elevated liver enzymes
  • Myopathy or rhabdomyolysis (especially with statins)
  • Severe allergic reactions such as rash or angioedema
  • Acute pancreatitis
  • Hepatotoxicity

Precautions & Warnings

Before initiating Mibezet, clinicians should consider several precautionary measures to ensure safe use.

  • Liver function monitoring: assess baseline transaminases and repeat periodically during therapy.
  • Lipid profile assessment: evaluate LDL‑cholesterol response after 4–12 weeks.
  • Gallbladder disease evaluation: use caution in patients with a history of gallstones.
  • Hepatic impairment: adjust therapy or avoid use in severe liver disease.
  • Drug combination caution: avoid concomitant use with strong CYP3A4 inhibitors without supervision.
  • Store below 25°C: keep in the original packaging, protect from moisture and light.

Avoid Interactions

Ezetimibe may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Cyclosporine: increases ezetimibe plasma concentrations, raising risk of adverse effects.
  • Gemfibrozil: may enhance ezetimibe exposure and potential muscle toxicity.
  • Bile acid sequestrants (e.g., cholestyramine): bind ezetimibe in the gut, markedly reducing its absorption.

Moderate Interactions (Monitor Closely)

  • Statins (especially high‑intensity): combined use can increase risk of myopathy; monitor muscle symptoms and CK levels.
  • Warfarin: ezetimibe may affect INR; check coagulation parameters regularly.
  • Antifungal azoles (ketoconazole, itraconazole): may modestly increase ezetimibe levels; observe for side effects.

Frequently Asked Questions

Mibezet contains ezetimibe and is prescribed to lower elevated blood cholesterol levels. It is indicated for patients with hypercholesterolemia, heterozygous familial hypercholesterolemia, and primary hyperlipidemia, either as monotherapy or in combination with other lipid‑lowering agents.

Ezetimibe blocks the NPC1L1 transporter on intestinal cells, preventing the absorption of dietary and biliary cholesterol. This reduces the amount of cholesterol delivered to the liver, prompting the liver to increase LDL‑receptor activity and lower circulating LDL‑cholesterol.

The prescribed dose of Mibezet is determined by the treating physician based on the patient’s clinical condition, lipid profile, and any concomitant therapy. Dosage adjustments are made according to individual response and safety considerations.

Safety data for ezetimibe during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike statins, which inhibit hepatic cholesterol synthesis, ezetimibe (Mibezet) reduces intestinal cholesterol absorption. It is often added to statin therapy for additional LDL‑cholesterol reduction, offering a complementary mechanism without overlapping metabolic pathways.

Mibezet should be stored below 25 °C in its original packaging. Keep the product away from moisture and direct light to maintain stability and potency throughout its shelf life.

Mibezet is taken orally as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food, according to the prescribing clinician’s instructions.

Serious adverse events, although rare, include elevated liver enzymes, muscle injury such as myopathy or rhabdomyolysis (especially when combined with statins), severe allergic reactions, and acute pancreatitis. Patients should report any unexplained muscle pain, jaundice, or rash promptly.

Mibezet is contraindicated in individuals with known hypersensitivity to ezetimibe or any excipients in the formulation, and it should be avoided in patients with active severe liver disease. Caution is also advised for those with gallbladder disease or significant hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ezetimibe

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT